A Prospective, Open Label, Multicenter, Single Arm, Phase 2 Study of 177Lu-PSMA-617 in the Treatment of Participants With Progressive PSMA- Positive Metastatic Castration-resistant Prostate Cancer (mCRPC) in Japan
Latest Information Update: 20 Mar 2026
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Antineoplastics
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Mar 2026 Planned End Date changed from 30 Apr 2026 to 25 Jun 2026.
- 16 Mar 2026 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2025 Planned End Date changed from 31 Jan 2028 to 30 Apr 2026.